Aurinia Pharmaceuticals (AUPH)
(Delayed Data from NSDQ)
$7.18 USD
-0.02 (-0.28%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $7.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
AUPH 7.18 -0.02(-0.28%)
Will AUPH be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AUPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AUPH
Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
AUPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
Other News for AUPH
Commit To Buy Aurinia Pharmaceuticals At $5, Earn 16% Using Options
Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024
Aurinia Announces Japan Approval of LUPKYNIS? (Voclosporin) to Treat Lupus Nephritis
3 Small Biotech Stocks With The 'Big Mo' Right Now
Aurinia Pharmaceuticals: LUPKYNIS Leading The Way In Lupus Nephritis Treatment